CytomX Therapeutics has appointed Dr Rachel Humphrey as chief medical officer.
Humphrey, who has served on the board of the directors at CytomX since March this year, was formerly VP and head of immuno-oncology at both Eli Lilly and AstraZeneca, supervising the development of numerous agents.
She said: “Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the Probody platform.
“I am excited to now be joining the management team to help build a great company that has the potential to make a real difference for patients.”
Sean McCarthy, CEO of CytomX, said: “We were thrilled to have Rachel join the board earlier this year, and having her now transition to the management team will allow us to benefit even more from her decades of experience in successful oncology product development and registration.”
Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer drug Yervoy (ipilimumab).
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).